Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

389 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.
Gallerani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, Hess D, Delmonte A, Martinelli G, Böhm S, Driessen C, De Braud F, Marsoni S, Cereda R, Sala F, D'Incalci M, Sessa C. Gallerani E, et al. Among authors: sessa c. Eur J Cancer. 2013 Jan;49(2):290-6. doi: 10.1016/j.ejca.2012.09.009. Epub 2012 Oct 8. Eur J Cancer. 2013. PMID: 23058787 Review.
Molecule-targeted agents in endometrial cancer.
Delmonte A, Sessa C. Delmonte A, et al. Among authors: sessa c. Curr Opin Oncol. 2008 Sep;20(5):554-9. doi: 10.1097/CCO.0b013e32830b0deb. Curr Opin Oncol. 2008. PMID: 19106660 Review.
Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.
Frapolli R, Zucchetti M, Sessa C, Marsoni S, Viganò L, Locatelli A, Rulli E, Compagnoni A, Bello E, Pisano C, Carminati P, D'Incalci M. Frapolli R, et al. Among authors: sessa c. Eur J Cancer. 2010 Feb;46(3):505-16. doi: 10.1016/j.ejca.2009.11.006. Epub 2009 Dec 16. Eur J Cancer. 2010. PMID: 20007015 Clinical Trial.
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
Perotti A, Locatelli A, Sessa C, Hess D, Viganò L, Capri G, Maur M, Cerny T, Cresta S, Rojo F, Albanell J, Marsoni S, Corradino I, Berk L, Rivera VM, Haluska F, Gianni L. Perotti A, et al. Among authors: sessa c. J Clin Oncol. 2010 Oct 20;28(30):4554-61. doi: 10.1200/JCO.2009.27.5867. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855840 Clinical Trial.
A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
Gallerani E, Bauer J, Hess D, Boehm S, Droege C, Jeckelmann S, Miani M, Herrmann R, Marsoni S, Sperka S, Sessa C. Gallerani E, et al. Among authors: sessa c. Acta Oncol. 2011 Oct;50(7):1105-10. doi: 10.3109/0284186X.2010.543697. Epub 2010 Dec 27. Acta Oncol. 2011. PMID: 21184645 Clinical Trial.
389 results